Pelion’s YTD and Q3 2016 financial performance
Pelion’s consolidated revenue for the first three quarters of 2016 rose more than 8%, to PLN 6.8bn, driven by consistent pursuit of a sales growth strategy across all business lines.
In Q3 2016 alone, sales grew by more than 5%, to PLN 2.2bn.
Adjusted for one-off items, EBITDA and EBIT also grew in Q1−Q3 2016 − by 10.9% and 8.3% yoy, respectively. In Q3 2016, the growth (adjusted for one-off item reported in Q3 2015) was +8.0% yoy for EBITDA and +3.2% yoy for EBIT.
Pelion continues to strategically strengthen its position in all business areas while implementing innovative solutions, to best respond to the growing needs and expectations of its Customers and Patients.
DOZ Apteki dbam o zdrowie pharmacies, which celebrate their 15th anniversary this year, provide reliable, professional and safe service to Patients, guaranteeing full availability of drugs at affordable prices. They are an important place to anyone interested in disease prevention and health protection, consciously caring for their well-being. In this spirit, DOZ pharmacies keep developing, improving and raising the quality of service. They are also a solid employer for Poland’s largest group of licensed pharmacists and pharmacy technicians, who pursue their professional mission by helping Patients with passion and commitment.
Natura beauty stores add new products to their offerings and improve their services, in cooperation with Polish manufacturers.
Polska Grupa Farmaceutyczna consistently develops its services for pharmacies, to make sure they meet Pharmacists’ expectations and support them in day-to-day patient care.
PGF Urtica seeks to continue as leader of the Polish market of drug supplies to hospitals. Since August 2016, the company has made deliveries from its central warehouse in Łódź. From this modern facility, Poland’s largest pharmaceutical warehouse, drugs are distributed to hospital pharmacies to reach about every third in-patient.
The table below presents the financial highlights for Q1−Q3 2016, along with comparative year-on-year data.
| I-IIIQ 2016 | I-IIIQ 2015 | Change* | |
| Revenue (PLNm | 6 834,4 | 6 319,5 | +8,1% |
| Gross profit (PLNm) | 791,9 | 736,4 | +7,5% |
| Gross margin | 11,6% | 11,7% | -0,1 pp |
| EBITDA factoring out the one-off (PLNm) | 108,4 | 100,0 | +8,4% |
| EBITDA margin factoring out the one-off | 1,6% | 1,6% | 0,0 pp |
| Net profit attributable to owners of the parent (PLNm) | 22,8 | 19,6 | +16,2% |
| Net margin | 0,3% | 0,3% | 0,0 pp |
*Change calculated based on figures in PLN ‘000
For further information, please contact:
Pelion S.A. Press Office
Phone: (+48 42) 200 75 94
Fax: (+48 42) 200 75 35
Email: biuro_prasowe@pelion.eu
Pelion S.A. has operated on the market for twenty-six years, starting out as a local pharmaceutical wholesaler. In 1998, the Company shares were floated on the Warsaw Stock Exchange. Proceeds from the initial public offering fuelled the Company’s dynamic growth and allowed it to embark on consolidation of the pharmaceutical wholesale market. Today, Pelion Healthcare Group is one of the largest groups operating in the healthcare markets in Poland and Lithuania. It provides services across all market segments (wholesale, retail sales and sales to hospitals), targeted at individual patients, pharmacies, hospitals, and manufacturers. As a holding company, Pelion S.A. oversees all areas of the Company’s operations, which are conducted by PGF S.A. and Pharmapoint S.A. (wholesale), CEPD N.V. (retail) and PGF Urtica Sp. z o.o. and Pharmalink Sp. z o.o. (hospital supplies and logistics services).
